Silvio Antoniak1, Kohei Tatsumi2, Clare M Schmedes3, Steven P Grover3, Rafal Pawlinski3, Nigel Mackman3. 1. Department of Medicine, Thrombosis and Hemostasis Program, Division of Hematology and Oncology, UNC McAllister Heart Institute, University of North Carolina, Chapel Hill, NC, United States; Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States. Electronic address: antoniak@email.unc.edu. 2. Department of Medicine, Thrombosis and Hemostasis Program, Division of Hematology and Oncology, UNC McAllister Heart Institute, University of North Carolina, Chapel Hill, NC, United States; Department of Physiology and Regenerative Medicine, Kindai University, Faculty of Medicine, Osaka-sayama, Osaka, Japan. 3. Department of Medicine, Thrombosis and Hemostasis Program, Division of Hematology and Oncology, UNC McAllister Heart Institute, University of North Carolina, Chapel Hill, NC, United States.
Abstract
OBJECTIVE: The anti-cancer anthracycline drug Doxorubicin (Dox) causes cardiotoxicity. We investigated the role of protease-activated receptor 1 (PAR-1) in Dox-induced cardiotoxicity. METHODS AND RESULTS: In vitro experiments revealed that PAR-1 enhanced Dox-induced mitochondrial dysfunction, reactive oxygen species and cell death of cardiac myocytes and cardiac fibroblasts. The contribution of PAR-1 to Dox-induced cardiotoxicity was investigated by subjecting PAR-1-/- mice and PAR-1+/+ mice to acute and chronic exposure to Dox. Heart function was measured by echocardiography. PAR-1-/- mice exhibited significant less cardiac injury and dysfunction compared to PAR-1+/+ mice after acute and chronic Dox administration. PAR-1-/- mice had reduced levels of nitrotyrosine, apoptosis and inflammation in their heart compared to PAR-1+/+ mice. Furthermore, inhibition of PAR-1 in wild-type mice with vorapaxar significantly reduced the acute Dox-induced cardiotoxicity. CONCLUSION: Our results indicate that activation of PAR-1 contributes to Dox-induced cardiotoxicity. Inhibition of PAR-1 may be a new approach to reduce Dox-induced cardiotoxicity in cancer patients.
OBJECTIVE: The anti-canceranthracycline drug Doxorubicin (Dox) causes cardiotoxicity. We investigated the role of protease-activated receptor 1 (PAR-1) in Dox-induced cardiotoxicity. METHODS AND RESULTS: In vitro experiments revealed that PAR-1 enhanced Dox-induced mitochondrial dysfunction, reactive oxygen species and cell death of cardiac myocytes and cardiac fibroblasts. The contribution of PAR-1 to Dox-induced cardiotoxicity was investigated by subjecting PAR-1-/- mice and PAR-1+/+ mice to acute and chronic exposure to Dox. Heart function was measured by echocardiography. PAR-1-/- mice exhibited significant less cardiac injury and dysfunction compared to PAR-1+/+ mice after acute and chronic Dox administration. PAR-1-/- mice had reduced levels of nitrotyrosine, apoptosis and inflammation in their heart compared to PAR-1+/+ mice. Furthermore, inhibition of PAR-1 in wild-type mice with vorapaxar significantly reduced the acute Dox-induced cardiotoxicity. CONCLUSION: Our results indicate that activation of PAR-1 contributes to Dox-induced cardiotoxicity. Inhibition of PAR-1 may be a new approach to reduce Dox-induced cardiotoxicity in cancerpatients.
Authors: Vladislava O Melnikova; Krishnakumar Balasubramanian; Gabriel J Villares; Andrey S Dobroff; Maya Zigler; Hua Wang; Frederik Petersson; Janet E Price; Alan Schroit; Victor G Prieto; Mien-Chie Hung; Menashe Bar-Eli Journal: J Biol Chem Date: 2009-08-24 Impact factor: 5.157
Authors: Alexander A Boucher; Leah Rosenfeldt; Duaa Mureb; Jessica Shafer; Bal Krishan Sharma; Adam Lane; Rebecca R Crowther; Melanie C McKell; Jordan Whitt; Theresa Alenghat; Joseph Qualls; Silvio Antoniak; Nigel Mackman; Matthew J Flick; Kris A Steinbrecher; Joseph S Palumbo Journal: J Thromb Haemost Date: 2019-10-11 Impact factor: 5.824
Authors: Michael F Bode; Clare M Schmedes; Grant J Egnatz; Vanthana Bharathi; Yohei M Hisada; David Martinez; Tomohiro Kawano; Alice Weithauser; Leah Rosenfeldt; Ursula Rauch; Joseph S Palumbo; Silvio Antoniak; Nigel Mackman Journal: Sci Rep Date: 2021-07-12 Impact factor: 4.996
Authors: Erica M Sparkenbaugh; Chunsheng Chen; Tomasz Brzoska; Julia Nguyen; Shaobin Wang; Gregory M Vercellotti; Nigel S Key; Prithu Sundd; John D Belcher; Rafal Pawlinski Journal: Blood Date: 2020-05-14 Impact factor: 25.476
Authors: Harald Krenzlin; Christina Frenz; Jan Schmitt; Julia Masomi-Bornwasser; Dominik Wesp; Darius Kalasauskas; Thomas Kerz; Johannes Lotz; Beat Alessandri; Florian Ringel; Naureen Keric Journal: PLoS One Date: 2020-11-11 Impact factor: 3.240